ENGAGE AF: Effective anticoagulation with factor Xa in next generation treatment of atrial fibrillation

Riyaz A Kaba, Omar Ahmed, Douglas Cannie


Recent trials have presented compelling evidence for the safety and efficacy of the new oral anticoagulants (NOACs) versus warfarin for stroke prevention in patients with atrial fibrillation (AF). The ENGAGE AF-TIMI 48 trial, the biggest of these trials, aims to evaluate the use of the direct factor Xa inhibitor, edoxaban. 

Full Text:



  • There are currently no refbacks.

Copyright (c) 2017 Riyaz A Kaba, Omar Ahmed, Douglas Cannie

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.